Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
In last month's newsletter, we discussed the recently decided case <i>In Re K-Dur Antitrust Litigation</i>,in which the Third Circuit bucked the trend of rubber-stamping pay-for-delay patent lawsuit settlements. The discussion concludes herein.
The fastest way to a mistrial is to mention the word "insurance" in front of the jury. This maxim refers to the collateral source rule. But what about the words "public benefits" or "special education"?
Features
Robotic technology may spawn both medical malpractice and product liability exposures, claims and lawsuits. Suits and claims may arise from one area or both. Here's what you need to know.
Features
This article provides an in-depth discussion of the concept of common-law indemnification, using New York State to illustrate how the law has evolved in that state. Be aware that many states have their own peculiarities that must be identified at the outset of any litigation so that an appropriate strategy can be devised.
The U.S. Supreme Court's recent decision in <i>Christopher v. SmithKline Beecham Corp.</i> was not only a landmark decision for the pharmaceutical industry, but also provided important guidance for the application of the outside sales exemption in other settings
Features
In late June, the Third Circuit considered the broad definition of "employer" under the FLSA to determine when two employers jointly employ an employee, an issue that has been arising with increasing frequency.
The U.S. Supreme Court's recent decision in <i>Christopher v. SmithKline Beecham Corp.</i> was not only a landmark decision for the pharmaceutical industry, but also provided important guidance for the application of the outside sales exemption in other settings.
